MedPath

Instituto Nacional de Enfermedades Respiratorias

🇲🇽Mexico
Ownership
-
Employees
-
Market Cap
-
Website
http://www.iner.salud.gob.mx/

Clinical Trials

16

Active:0
Completed:5

Trial Phases

3 Phases

Phase 2:1
Phase 4:1
Not Applicable:10

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials

Not Applicable
10 (83.3%)
Phase 2
1 (8.3%)
Phase 4
1 (8.3%)

Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia

Not Applicable
Not yet recruiting
Conditions
Primary Ciliary Dyskinesia
First Posted Date
2025-05-06
Last Posted Date
2025-05-30
Lead Sponsor
Instituto Nacional de Enfermedades Respiratorias
Target Recruit Count
60
Registration Number
NCT06959251
Locations
🇲🇽

Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico

Caspofungin for Pneumocystis Pneumonia in PLWHIV.

Recruiting
Conditions
HIV-1-infection
Pneumocystis Pneumonia
First Posted Date
2024-11-15
Last Posted Date
2024-11-19
Lead Sponsor
Instituto Nacional de Enfermedades Respiratorias
Target Recruit Count
60
Registration Number
NCT06691321
Locations
🇲🇽

Center for Research in Infectious Diseases (CIENI), Mexico City, Tlalpan, Mexico

Applying Artificial Intelligence to Identify Subphenotypes of Acute Kidney Injury in Mexican Patients With Severe COVID-19

Completed
Conditions
Acute Kidney Injury
COVID-19
First Posted Date
2024-06-24
Last Posted Date
2024-06-24
Lead Sponsor
Instituto Nacional de Enfermedades Respiratorias
Target Recruit Count
2934
Registration Number
NCT06471101
Locations
🇲🇽

Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico

Morphofunctional, Gene, Inflammation Molecules and Oxidative Stress Analysis in Kidney Tissue of COVID-19 Patients

Completed
Conditions
COVID-19
Inflammatory Response
Kidney Injury
Gene Amplification
Oxidative Stress
First Posted Date
2024-06-06
Last Posted Date
2024-06-27
Lead Sponsor
Instituto Nacional de Enfermedades Respiratorias
Target Recruit Count
40
Registration Number
NCT06444893
Locations
🇲🇽

National Institute of Respiratory Diseases, Mexico City, Ciudad DE México, Mexico

Renal Biomarkers in AKI and COVID-19

Completed
Conditions
Coronavirus Infection
Covid19
AKI
SARS (Severe Acute Respiratory Syndrome)
First Posted Date
2020-08-18
Last Posted Date
2024-06-06
Lead Sponsor
Instituto Nacional de Enfermedades Respiratorias
Target Recruit Count
51
Registration Number
NCT04517630
Locations
🇲🇽

Centro de Investigacion en Enfermedades Infecciosas, Mexico City, Mexico

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.